{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:21:43Z","timestamp":1790000503450,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vaccine.2014.11.026","type":"journal-article","created":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T23:50:34Z","timestamp":1416700234000},"page":"314-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Carrier priming with CRM197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation"],"prefix":"10.1016","volume":"33","author":[{"given":"S.","family":"Pecetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lo Surdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tontini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zambonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.11.026_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0010","first-page":"144","article-title":"Semi-synthetic vaccines composed of capsular polysaccharides of pathogenic bacteria covalently bound to proteins for the prevention of invasive diseases","volume":"33","author":"Schneerson","year":"1983","journal-title":"Prog Allergy"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0015","doi-asserted-by":"crossref","first-page":"628963","DOI":"10.1155\/2008\/628963","article-title":"Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines","volume":"2008","author":"Klein Klouwenberg","year":"2008","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0020","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein\u2013polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0025","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.147","article-title":"Menveo\u00ae: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0035","doi-asserted-by":"crossref","first-page":"B30","DOI":"10.1016\/j.vaccine.2009.05.003","article-title":"Quadrivalent meningococcal conjugate vaccines","volume":"27","author":"Pace","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/erv.12.32","article-title":"MenACWY-TT vaccine for active immunization against invasive meningococcal disease","volume":"11","author":"Papaevangelou","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0045","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0050","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/CVI.05438-11","article-title":"Effect of increased CRM197 carrier protein dose on meningococcal C bactericidal antibody response","volume":"19","author":"Lee","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0055","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1586\/erv.11.142","article-title":"Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules","volume":"10","author":"Borrow","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0060","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: characteristics, development and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0065","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1016\/j.vaccine.2013.07.078","article-title":"Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines","volume":"31","author":"Tontini","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0070","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1128\/IAI.59.10.3504-3510.1991","article-title":"Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines","volume":"59","author":"Peeters","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0075","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.vaccine.2014.01.047","article-title":"Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines","volume":"32","author":"Pobre","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0080","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","article-title":"Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages","volume":"27","author":"Br\u00f6ker","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0085","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/infdis\/142.5.716","article-title":"Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid","volume":"142","author":"Porro","year":"1980","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/CDLI.5.4.479-485.1998","article-title":"A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses","volume":"5","author":"Granoff","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0022-1759(86)90268-1","article-title":"Antibody avidity determination by ELISA using thiocyanate elution","volume":"86","author":"Pullen","year":"1986","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1042\/BA20000078","article-title":"Solution stability studies of the subunit components of meningococcal C oligosaccharide-CRM197 conjugate vaccines","volume":"33","author":"Ho","year":"2001","journal-title":"Biotechnol Appl Biochem"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389203003381315","article-title":"The use of circular dichroism in the investigation of protein structure and function","volume":"1","author":"Kelly","year":"2000","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0110","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.4049\/jimmunol.142.8.2635","article-title":"Carrier-induced epitopic suppression is initiated through clonal dominance","volume":"142","author":"Schutze","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0115","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0120","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1016\/S0264-410X(02)00342-0","article-title":"Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines","volume":"20","author":"Ho","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0125","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0130","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1084\/jem.155.6.1730","article-title":"Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses","volume":"155","author":"Herzenberg","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0135","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.155.6.1741","article-title":"Epitope-specific regulation. II. A bistable, Igh-restricted regulatory mechanism central to immunologic memory","volume":"155","author":"Herzenberg","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0140","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.161.2.702","article-title":"Carrier-induced, hapten-specific suppression: a problem of antigen presentation?","volume":"161","author":"Renjifo","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.11.026_bib0145","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4049\/jimmunol.145.5.1343","article-title":"The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression","volume":"145","author":"LeClerc","year":"1990","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14015655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14015655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T13:10:51Z","timestamp":1689685851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14015655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0264410X14015655"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carrier priming with CRM197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: Biophysical and immunochemical interpretation","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}